Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Hepatic Encephalopathy | Research

A novel nomogram to predict 90-day mortality in patients with hepatitis B virus-related acute-on-chronic liver failure: a single-center retrospective study

Authors: Ye Xiong, Zuoxun Xia, Lu Yang, Jianrong Huang

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Acute-on-chronic liver failure (ACLF) is a critical illness with high mortality. Herein, we developed and validated a new and simple prognostic nomogram to predict 90-day mortality in hepatitis B virus-related ACLF (HBV-ACLF) patients.

Methods

This single-center retrospective study collected data from 181 HBV-ACLF patients treated between June 2018 and March 2020. The correlation between clinical data and 90-day mortality in patients with HBV-ACLF was assessed using univariate and multivariate logistic regression analyses.

Results

Multivariate logistic regression analysis showed that age (p = 0.011), hepatic encephalopathy (p = 0.001), total bilirubin (p = 0.007), international normalized ratio (p = 0.006), and high-density lipoprotein cholesterol (p = 0.011) were independent predictors of 90-day mortality in HBV-ACLF patients. A nomogram was created to predict 90-day mortality using these risk factors. The C-index for the prognostic nomogram was calculated as 0.866, and confirmed to be 0.854 via bootstrapping verification. The area under the curve was 0.870 in the external validation cohort. The predictive value of the nomogram was similar to that of the Chinese Group on the Study of Severe Hepatitis B score, and exceeded the performance of other prognostic scores.

Conclusion

The prognostic nomogram constructed using the factors identified in multivariate regression analysis might serve as a beneficial tool to predict 90-day mortality in HBV-ACLF patients.
Literature
1.
go back to reference Khanam A, Kottilil S. Acute-on-chronic liver failure: pathophysiological mechanisms and management. Front Med (Lausanne). 2021;8:752875.CrossRefPubMed Khanam A, Kottilil S. Acute-on-chronic liver failure: pathophysiological mechanisms and management. Front Med (Lausanne). 2021;8:752875.CrossRefPubMed
2.
go back to reference Sarin SK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353–90.CrossRefPubMed Sarin SK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353–90.CrossRefPubMed
5.
go back to reference Chen EQ, et al. Early warning and clinical outcome prediction of acute-on-chronic hepatitis B liver failure. World J Gastroenterol. 2015;21(42):11964–73.CrossRefPubMedPubMedCentral Chen EQ, et al. Early warning and clinical outcome prediction of acute-on-chronic hepatitis B liver failure. World J Gastroenterol. 2015;21(42):11964–73.CrossRefPubMedPubMedCentral
6.
go back to reference Wu D, et al. HINT: a novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure. Aliment Pharmacol Ther. 2018;48(7):750–60.CrossRefPubMed Wu D, et al. HINT: a novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure. Aliment Pharmacol Ther. 2018;48(7):750–60.CrossRefPubMed
8.
go back to reference Zhao RH, et al. Acute-on-chronic liver failure in chronic hepatitis B: an update. Expert Rev Gastroenterol Hepatol. 2018;12(4):341–50.CrossRefPubMed Zhao RH, et al. Acute-on-chronic liver failure in chronic hepatitis B: an update. Expert Rev Gastroenterol Hepatol. 2018;12(4):341–50.CrossRefPubMed
9.
go back to reference Huang K, et al. Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: classification and regression tree analysis. Sci Rep. 2019;9(1):16462.CrossRefPubMedPubMedCentral Huang K, et al. Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: classification and regression tree analysis. Sci Rep. 2019;9(1):16462.CrossRefPubMedPubMedCentral
10.
go back to reference Kribben A, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(4):782-789.e3.CrossRefPubMed Kribben A, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(4):782-789.e3.CrossRefPubMed
12.
go back to reference Goosmann L, et al. Liver transplantation for acute-on-chronic liver failure predicts post-transplant mortality and impaired long-term quality of life. Liver Int. 2021;41(3):574–84.CrossRefPubMed Goosmann L, et al. Liver transplantation for acute-on-chronic liver failure predicts post-transplant mortality and impaired long-term quality of life. Liver Int. 2021;41(3):574–84.CrossRefPubMed
13.
go back to reference Wiesner R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–6.CrossRefPubMed Wiesner R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–6.CrossRefPubMed
14.
go back to reference Jalan R, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038–47.CrossRefPubMed Jalan R, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038–47.CrossRefPubMed
15.
go back to reference Wu T, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2018;67(12):2181–91.CrossRefPubMed Wu T, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2018;67(12):2181–91.CrossRefPubMed
16.
18.
go back to reference Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109–23.CrossRefPubMed Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109–23.CrossRefPubMed
19.
go back to reference Shah S, Goldberg DS. Acute-on-chronic liver failure: update on pathogenesis, therapeutic targets, predictive models, and liver transplantation. Curr Opin Gastroenterol. 2021;37(3):173–8.CrossRefPubMed Shah S, Goldberg DS. Acute-on-chronic liver failure: update on pathogenesis, therapeutic targets, predictive models, and liver transplantation. Curr Opin Gastroenterol. 2021;37(3):173–8.CrossRefPubMed
20.
22.
go back to reference Cai JJ, et al. Characteristics, risk factors, and adverse outcomes of hyperkalemia in acute-on-chronic liver failure patients. Biomed Res Int. 2019;2019:6025726.CrossRefPubMedPubMedCentral Cai JJ, et al. Characteristics, risk factors, and adverse outcomes of hyperkalemia in acute-on-chronic liver failure patients. Biomed Res Int. 2019;2019:6025726.CrossRefPubMedPubMedCentral
23.
go back to reference Peng Y, et al. Prediction and risk factors for prognosis of cirrhotic patients with hepatic encephalopathy. Gastroenterol Res Pract. 2021;2021:5623601.CrossRefPubMedPubMedCentral Peng Y, et al. Prediction and risk factors for prognosis of cirrhotic patients with hepatic encephalopathy. Gastroenterol Res Pract. 2021;2021:5623601.CrossRefPubMedPubMedCentral
24.
go back to reference Choudhury A, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. 2017;11(5):461–71.CrossRefPubMed Choudhury A, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. 2017;11(5):461–71.CrossRefPubMed
25.
go back to reference Said A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40(6):897–903.CrossRefPubMed Said A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40(6):897–903.CrossRefPubMed
26.
go back to reference Cordoba J, et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol. 2014;60(2):275–81.CrossRefPubMed Cordoba J, et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol. 2014;60(2):275–81.CrossRefPubMed
27.
go back to reference Verma N, et al. Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure. Hepatol Int. 2021;15(4):970–82.CrossRefPubMed Verma N, et al. Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure. Hepatol Int. 2021;15(4):970–82.CrossRefPubMed
28.
go back to reference Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008;14(8 Suppl):S3-28; quiz S30-1.PubMed Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008;14(8 Suppl):S3-28; quiz S30-1.PubMed
29.
go back to reference Lu Q, et al. Low HDL-C predicts risk and PCI outcomes in the Han Chinese population. Atherosclerosis. 2013;226(1):193–7.CrossRefPubMed Lu Q, et al. Low HDL-C predicts risk and PCI outcomes in the Han Chinese population. Atherosclerosis. 2013;226(1):193–7.CrossRefPubMed
30.
31.
go back to reference Trieb M, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. J Hepatol. 2020;73(1):113–20.CrossRefPubMed Trieb M, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. J Hepatol. 2020;73(1):113–20.CrossRefPubMed
32.
go back to reference Gong X, et al. Associations of lipid profiles with the risk of ischemic and hemorrhagic stroke: a systematic review and meta-analysis of prospective cohort studies. Front Cardiovasc Med. 2022;9:893248.CrossRefPubMedPubMedCentral Gong X, et al. Associations of lipid profiles with the risk of ischemic and hemorrhagic stroke: a systematic review and meta-analysis of prospective cohort studies. Front Cardiovasc Med. 2022;9:893248.CrossRefPubMedPubMedCentral
34.
go back to reference Silbernagel G, et al. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J. 2013;34(46):3563–71.CrossRefPubMed Silbernagel G, et al. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J. 2013;34(46):3563–71.CrossRefPubMed
35.
go back to reference Sorrentino SA, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121(1):110–22.CrossRefPubMed Sorrentino SA, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121(1):110–22.CrossRefPubMed
37.
go back to reference Speer T, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity. 2013;38(4):754–68.CrossRefPubMed Speer T, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity. 2013;38(4):754–68.CrossRefPubMed
38.
go back to reference Chen JF, et al. Derivation and validation of a nomogram for predicting 90-day survival in patients with HBV-Related Acute-on-Chronic Liver Failure. Front Med (Lausanne). 2021;8:692669.CrossRefPubMed Chen JF, et al. Derivation and validation of a nomogram for predicting 90-day survival in patients with HBV-Related Acute-on-Chronic Liver Failure. Front Med (Lausanne). 2021;8:692669.CrossRefPubMed
Metadata
Title
A novel nomogram to predict 90-day mortality in patients with hepatitis B virus-related acute-on-chronic liver failure: a single-center retrospective study
Authors
Ye Xiong
Zuoxun Xia
Lu Yang
Jianrong Huang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02727-1

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.